UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the (read more)
UTRF in the News
University of Tennessee Technology and Research on the Forefront of COVID-19 Fight
“AUTM’s recognition of Dr. Peter Tsai and Dr. Michael Whitt emphasizes the high-caliber research and technology coming out of the UT System…”, UTRF President Dr. Stacey Patterson.
UTRF, UTHSC, and Anviron Partner to Commercialize Novel Treatment for Pancreatic Cancer
A Mission for Making Good Medicine The University of Tennessee Research Foundation (UTRF), the University of Tennessee Health Science Center (UTHSC), and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel treatment with promising efficacy against pancreatic cancer tumors. According to the Genetic and Rare Diseases Information Center, the total number of (read more)